NOTCH1 and B-cell chronic lymphocytic leukemia: Mutations in NOTCH1 itself or in NOTCH1 regulators and active NOTCH1 signaling in CLL are predictive factors for dismal prognosis and poor response to anti-CD20 antibodies used in the therapy of CLL [5–9].